Method of treating amyloidosis by modulation of calcium
US5538983A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 29, 1994 |
| Grant date | Jul 23, 1996 |
| Priority date | — |
| Expiry date | Apr 29, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various first messengers linked to phospholipase C, including acetylcholine and interleukin-1, regulate the production both of the secreted form of the amyloid protein precursor and of amyloid .beta.-protein. Intracellular signals which are responsible for mediating these effects have now been identified, and that activation of phospholipase C may affect APP processing by either of two pathways, one involving an increase in protein kinase C and the other an increase in cytoplasmic calcium levels. The effects of calcium on APP processing appear to be independent of protein kinase C activation. The observed effects of calcium on APP processing are of therapeutic utility in the treatment of Alzheimer-type amyloidosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.